Sponsored by
This is the latest version of CUSP9 (CUSP9v3)
This is a very small study so obviously has to be repeated with larger numbers but they have impressive data. Looking at the survival curve for survival, progression free survival at 12 months was 50% which is pretty good. However, of the 5 patients who lived that long, none of them did yet, so there is a tail of the curve that doesn't drop below the 50% survival point.
This is a for a cocktail of repurposed drugs that are easily available, in addition to Temozolomide.